Navigation Links
Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
Date:10/30/2008

CAMBRIDGE, Mass., Oct. 30 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases, today reported unaudited financial results for the third quarter and nine months ended September 30, 2008. At September 30, 2008, Idenix's cash, cash equivalents and marketable securities totaled approximately $60.1 million.

2008 Year-to-Date Business Highlights

-- Idenix completed its phase I/II study of IDX899, a non-nucleoside reverse transcriptase inhibitor (NNRTI) being developed for the treatment of HIV-1, which demonstrated potent antiviral activity at all doses tested. Patients receiving once-daily IDX899 achieved a mean plasma viral load reduction of approximately 1.8 log10 after seven days of treatment in each of the 800 mg, 400 mg, 200 mg and 100 mg dosing cohorts (n=8 per treatment group). Patients receiving placebo (n=8) had a mean viral load increase of 0.10 log10 over the same treatment period. The safety profile of IDX899 observed during this study was comparable to placebo, with no serious adverse events reported and no pattern of adverse events or laboratory abnormalities observed on treatment. Additionally, no patients who received treatment discontinued the study.

-- Idenix also continued to advance its HCV discovery and development programs, successfully completing a first-in-man phase I study of IDX184, a nucleotide prodrug candidate, and initiating the IND-enabling preclinical studies for IDX375, a non-nucleoside polymerase inhibitor, and IDX136 and IDX316, macrocyclic protease inhibitor drug candidates.

"As we advance our HCV and HIV discovery and devel
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
2. Idenix to Host Conference Call Discussing Third Quarter 2007 Financial Results
3. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
4. Idenix to Host Conference Call Discussing Fourth Quarter 2007 Financial Results
5. Idenix Announces Data Presentations at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL)
6. Idenix Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
7. Idenix Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
8. Idenix Pharmaceuticals to Present at the Seventh Annual Needham and Company, LLC Biotechnology and Medical Technology Conference
9. Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results
10. Idenix Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
11. Idenix to Host Conference Call Discussing Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 2014 Today the National Institutes ... grants for the Brain Research through Advancing Innovative ... develop and revolutionize new methods of understanding the ... brain. This first round of grants totaling $46 ... allocated to more than 100 investigators in 15 ...
(Date:10/1/2014)... TeselaGen Biotechnology has received ... expand their bioCAD/CAM software suite, which uses synthetic ... Small Business Innovation Research Phase II grant will be ... license from the Lawrence Berkeley National Laboratory. j5 was ... LBNL laboratory that develops alternative fuel technologies for the ...
(Date:9/30/2014)... 2014 Applying a well-known optical phenomenon called ... University has demonstrated the ability to "paint" ultra-thin ... holds promise for making future, flexible electronic devices, ... of next-gen rocket ships and spacecraft with extremely ... oil in water, it becomes iridescent, revealing a ...
(Date:9/30/2014)... Shimadzu Scientific Instruments has released the DSES-1000 ... tool for measuring displacement in rubber and other ... movement distance, the DSES-1000 can measure elongations up ... 10 mm. In addition, it achieves +/- 0.2 ... within +/- 100 µm below 50-mm stroke. , ...
Breaking Biology Technology:NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 2NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 3TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Taking thin films to the extreme 2Shimadzu’s New Long-Travel Extensometer Increases Precision for Soft Material Testing 2
... announced that Ricky Takai, Ph.D., has joined the company ... the firm, Dr. Takai will become the leader of ... Takai brings his more than 20 years experience in ... the field of education to the company.Most recently, Dr. ...
... Inc. (Nasdaq: BMRN ) today announced ... placebo-controlled clinical study of 6R-BH4 in patients with ... no statistical significance observed between the 6R-BH4 treatment ... peak walking time (PWT), did not show a ...
... CHICAGO, Feb. 3 Advanced Life Sciences Holdings,Inc. (Nasdaq: ... the discovery,development and commercialization of novel drugs in the ... that the Company,will make a corporate presentation to investors ... Company,s presentation will be delivered in the Windsor Suite,at ...
Cached Biology Technology:Dr. Ricky Takai, Expert in Designing and Managing Federal Evaluation Studies in Education, Joins Abt Associates 2Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant 2Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant 3Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant 4Advanced Life Sciences to Present at the 11th Annual BIO CEO & Investor Conference 2Advanced Life Sciences to Present at the 11th Annual BIO CEO & Investor Conference 3
(Date:10/1/2014)... October 1, 2014 Novel ... life science field  The life science ... go over the years. Some are shooting stars ... is a novel detection technology that has raised ... finally, this technology is becoming commercially available. With ...
(Date:9/30/2014)... something that we enjoy when we visit a national park ... of ourselves as a part of nature? A bird,s nest ... , The answers to these questions reflect different cultural ... and in cultural artifacts. , A new Northwestern University study, ... Center of Chicago and the Menominee tribe of Wisconsin, focuses ...
(Date:9/30/2014)... and Howard Hughes Medical Institute investigator, and Margarita ... in the 2014 round of grants from the ... (Brain Research through Advancing Innovative Neurotechnologies) Initiative for ... 30, provides more than $3 million in funding ... The BRAIN Initiative, launched last year, is a ...
Breaking Biology News(10 mins):First-of-a-kind Solution for Utilizing Photon Upconversion 2The cultural side of science communication 2Salk scientists receive $3 million for BRAIN Initiative grant 2
... than a dozen countries joined together to sequence the tomato ... The Tomato Genomics Consortium directed the research effort, which ... Foundation and the USDA,s Agriculture Research Services. The OU ... Emeritus in the College of Arts and Sciences, was one ...
... 2012) -- A detailed analysis of more than 4 ... help electricity producers slash as much as 30 percent ... dioxide from power plant emissions. The research by ... Lawrence Berkeley National Laboratory (LBNL) and the Electric Power ...
... Madrid, May, 31st, 2012.- Madrid will become ... during the Biomedical Innovation Conference 2012, focused on ... Madrid-MIT M+Vision Consortium. This new organization has been ... and the regional Government of the Comunidad de ...
Cached Biology News:New materials could slash energy costs for CO2 capture 2New materials could slash energy costs for CO2 capture 3MADRID-MIT M+Vision Consortium hosts Biomedical Innovation Conference 2012 2
BD Falcon Center-well 60 mm In Vitro Fertilization (IVF) Dish, nonembryotoxic, noncytotoxic, tissue-culture treated polystyrene. (20/sp, 500/ca) Packaging: 20 / sleeve, 500 / case ...
... Collagen I 60 mm Culture Dishes BD ... treated polystyrene with a uniform application of rat ... Collagen I ,Surface : ECM/attachment ... ,Dim nominal : 60 mm x ...
...
The piston kit includes 2 pistons to service one F10 pump of a BioLogic DuoFlow workstation....
Biology Products: